Intra-Cellular Therapies to Present at the American Society of Clinical Psychopharmacology 2017 Annual Meeting
May 25 2017 - 8:00AM
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical
company focused on the development of therapeutics for central
nervous system (CNS) disorders, today announced it will present
four presentations at the American Society of Clinical
Psychopharmacology (ASCP) 2017 Annual Meeting being held
in Miami, FL, May 29 – June 2, 2017.
At ASCP, the Company will present an overview of the clinical
development program for lumateperone, including safety and efficacy
data and its potential for rapid antidepressant effects. This
presentation is entitled:
"Lumateperone (ITI-007): Late Stage Clinical Program in
Schizophrenia” to be presented Tuesday, May 30, 2017 at 5:05 – 5:20
pm ET during the Oral Session – Individual Research Report
Session: Advances in Schizophrenia Treatment and Assessment.
The Company will present preclinical and Phase I clinical data
supporting the clinical development of ITI-214, its novel
phosphodiesterase-1 (PDE1) inhibitor. In these presentations the
rationale behind ITI-214’s potential for the treatment of CNS
indications is described. ITI-214 has anti-inflammatory properties,
and as such, may be disease modifying in various neurodegenerative
disorders, including Parkinson’s and Alzheimer’s disease. Data
supporting the planned Phase 1/2 clinical trial in patients with
Parkinson's disease will also be presented. The presentations
are entitled:
"Rationale for the Clinical Development of ITI-214, a PDE1
Inhibitor” to be presented Tuesday, May 30, 2017 at 2:20 – 2:30 pm
ET during the Oral Session – Pharmaceutical Pipelines.
"Rationale for the Clinical Development of ITI-214, a PDE1
Inhibitor" to be presented on Thursday, June 1, 2017, 12:30
– 2:00 pm ET during Poster Session II (T47).
The Company will present an overview of ITI-333, a novel
modulator of serotonin, dopamine, and mu opiate receptors in
preclinical development for the potential treatment of mood
disorders including depression, substance use disorders and pain.
This presentation is entitled:
"Mechanism of Action of Novel Modulators of Serotonin, Dopamine,
and Mu Opiate Receptors for Treatment of Mood Disorders, Substance
Use Disorder and Pain" to be presented on Wednesday, May 31, 2017,
11:15 am – 1:00 pm ET during Poster Session I (W32).
About Intra-Cellular Therapies
Intra-Cellular Therapies is developing novel drugs for the
treatment of neuropsychiatric and neurodegenerative diseases and
diseases of the elderly, including Parkinson’s and Alzheimer’s
disease. The Company is developing its lead drug candidate,
lumateperone (also known as ITI-007), for the treatment of
schizophrenia, bipolar disorder, behavioral disturbances in
patients with dementia, including Alzheimer’s disease, depression
and other neuropsychiatric and neurological disorders.
Lumateperone, a first-in-class molecule, is in Phase 3 clinical
development for the treatment of schizophrenia, bipolar depression
and agitation associated with dementia, including Alzheimer’s
disease. The Company is also utilizing its phosphodiesterase
platform and other proprietary chemistry platforms to develop drugs
for the treatment of CNS and other disorders.
Forward-Looking Statements
This news release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties that could cause actual
results to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. Such forward-looking statements include statements
regarding, among other things, our clinical and non-clinical
development plans; the progress, timing and results of our clinical
trials and preclinical studies; our beliefs about the extent to
which the results of our clinical trials and preclinical studies to
date support new drug application filings for lumateperone; the
safety and efficacy of our product development candidates; our
beliefs about the potential uses and benefits of our drug product
candidates; our development plans for our PDE program, including
ITI-214 and development efforts and plans under the caption “About
Intra-Cellular Therapies.” All such forward-looking statements are
based on management's present expectations and are subject to
certain factors, risks and uncertainties that may cause actual
results, outcome of events, timing and performance to differ
materially from those expressed or implied by such statements.
These risks and uncertainties include but are not limited to the
following: our current and planned clinical trials, other studies
for lumateperone, and our other product candidates may not be
successful or may take longer and be more costly than anticipated;
product candidates that appeared promising in earlier research and
clinical trials may not demonstrate safety and/or efficacy in
larger-scale or later clinical trials; our proposals with respect
to the regulatory path for our product candidates may not be
acceptable to the FDA; our reliance on collaborative partners and
other third parties for development of our product candidates; and
the other risk factors detailed in our public filings with the
Securities and Exchange Commission. All statements contained
in this press release are made only as of the date of this press
release, and we do not intend to update this information unless
required by law.
Contact:
Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333
Burns McClellan, Inc.
Lisa Burns
Justin Jackson (Media)
jjackson@burnsmc.com
212-213-0006
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Apr 2023 to Apr 2024